Immunic, Inc. (IMUX)

6d ago, source: Yahoo Finance

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Immunic (NASDAQ: IMUX)

3d ago, source: The Motley Fool

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

Immunic secures key patent, boosting MS drug exclusivity and global IP strategy

29d ago, source: Yahoo Finance

Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with news the company has received a Notice of Allowance from the US Patent and Trademark Office for a new patent application ...

Immunic Stock (NASDAQ:IMUX), Analyst Ratings, Price Targets, Predictions

14d ago, source: Benzinga.com

Immunic Inc has a consensus price target of $21, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from Brookline Capital, Wedbush, and Wedbush on ...

Immunic receives US patent covering the composition-of-matter of a specific polymorph of vidofludimus calcium

27d ago, source: Pharmabiz

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that it has received ...

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

29d ago, source: FOX59 News

NEW YORK, March 20, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic ...

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)

3d ago, source:

Analysts fell to the sidelines weighing in on Adaptimmune Therapeutics (ADAP – Research Report) and Immunic (IMUX – Research Report) with ...

Immunic granted patent for specific polymorph of vidofludimus calcium in US

29d ago, source: Proactiveinvestors

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...

Immunic Inc IMUX

8d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...